Kenneth Carl Anderson

CIK: 0001824862

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)1 (8.3%)

Derivative conversions

Awards (A)11 (91.7%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

CCCC

C4 Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (12 total)

CCCC
C4 Therapeutics, Inc.
Oct 1, 2026
Award(A)
Direct
3.7K shares at avg. $3.14$11K
CCCC
C4 Therapeutics, Inc.
Jul 1, 2026
Award(A)
Direct
2.7K shares at avg. $4.34$12K
CCCC
C4 Therapeutics, Inc.
Jun 24, 2026
Award(A)
Stock Option (Right to Buy)
Direct
62K shares-
CCCC
C4 Therapeutics, Inc.
Jun 1, 2026
Exercise(M)
Direct
1.1K shares at avg. $2.11$2K
CCCC
C4 Therapeutics, Inc.
Apr 1, 2026
Award(A)
Direct
4.3K shares at avg. $2.70$11K
CCCC
C4 Therapeutics, Inc.
Jan 2, 2026
Award(A)
Direct
6K shares at avg. $1.93$11K
CCCC
C4 Therapeutics, Inc.
Oct 1, 2025
Award(A)
Direct
5.3K shares at avg. $2.15$12K
CCCC
C4 Therapeutics, Inc.
Jul 1, 2025
Award(A)
Direct
7.6K shares at avg. $1.51$12K
CCCC
C4 Therapeutics, Inc.
Jun 18, 2025
Award(A)
Stock Option (Right to Buy)
Direct
35.5K shares-
CCCC
C4 Therapeutics, Inc.
Apr 1, 2025
Award(A)
Direct
7.8K shares at avg. $1.44$11K
CCCC
C4 Therapeutics, Inc.
Jan 2, 2025
Award(A)
Direct
3.1K shares at avg. $3.66$11K
CCCC
C4 Therapeutics, Inc.
Oct 1, 2024
Award(A)
Direct
2K shares at avg. $5.56$11K

		Type	Shares	Price		Ownership
Oct 1, 2026	CCCC C4 Therapeutics, Inc.	Award(A)	3,662	$3.14	$11,499	Direct
Jul 1, 2026	CCCC C4 Therapeutics, Inc.	Award(A)	2,650	$4.34	$11,501	Direct
Jun 24, 2026	CCCC C4 Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	62,000	-	-	Direct
Jun 1, 2026	CCCC C4 Therapeutics, Inc.	Exercise(M)	1,070	$2.11	$2,258	Direct
Apr 1, 2026	CCCC C4 Therapeutics, Inc.	Award(A)	4,259	$2.70	$11,499	Direct
Jan 2, 2026	CCCC C4 Therapeutics, Inc.	Award(A)	5,958	$1.93	$11,499	Direct
Oct 1, 2025	CCCC C4 Therapeutics, Inc.	Award(A)	5,349	$2.15	$11,500	Direct
Jul 1, 2025	CCCC C4 Therapeutics, Inc.	Award(A)	7,616	$1.51	$11,500	Direct
Jun 18, 2025	CCCC C4 Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	35,500	-	-	Direct
Apr 1, 2025	CCCC C4 Therapeutics, Inc.	Award(A)	7,841	$1.44	$11,252	Direct
Jan 2, 2025	CCCC C4 Therapeutics, Inc.	Award(A)	3,074	$3.66	$11,251	Direct
Oct 1, 2024	CCCC C4 Therapeutics, Inc.	Award(A)	2,023	$5.56	$11,248	Direct

1-12 of 12 transactions

About Anderson Kenneth Carl

Anderson Kenneth Carl (SEC CIK 0001824862) files insider reports with the SEC as Director of C4 Therapeutics, Inc. (CCCC).

Signal8 holds 12 ownership filings by Anderson Kenneth Carl, all Form 4s, filed between Oct 2, 2024 and Oct 2, 2026. Those filings report 12 transactions, from Oct 1, 2024 to Oct 1, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Anderson Kenneth Carl's filings is in WATERTOWN, MA.

Recent filings by Anderson Kenneth Carl

Oct 1, 2026: Grant or award of CCCC shares (Form 4, code A).
Jul 1, 2026: Grant or award of CCCC shares (Form 4, code A).
Jun 24, 2026: Grant or award of CCCC derivative securities (Form 4, code A).
Jun 1, 2026: Option exercise of CCCC shares (Form 4, code M).
Apr 1, 2026: Grant or award of CCCC shares (Form 4, code A).

Other insiders filing for C4 Therapeutics, Inc. (CCCC)

GROGAN DONNA ROY, Director
Adams Kendra, Chief Financial Officer
REYNO LEONARD, Chief Medical Officer
Hughes Owen, Director
Hoerter Steven L., Director
Koppikar Utpal, Director

How to read Form 4 transaction codes